Core Insights - The article highlights the acceleration of globalization among Chinese pharmaceutical and biotechnology companies during the "14th Five-Year Plan" period, emphasizing breakthroughs in innovative drugs and medical devices [1] - The strategy of "going global" is identified as a key approach for these companies to expand their business footprint and enhance core competitiveness and brand influence [1] Group 1: Industry Overview - As of the end of 2024, nearly 500 companies in the A-share pharmaceutical and biotechnology sector are noted, with overseas business revenue reaching 269.04 billion yuan, accounting for 10.90% of total revenue, reflecting an 11.00% year-on-year growth [2] - The transition from "product going global" to "brand going global" is highlighted as a significant shift for Chinese pharmaceutical companies [2] Group 2: Company Strategies - Baiyoutai's journey exemplifies the path of Chinese innovative drugs going global, having established an international standard R&D platform and completed global Phase III clinical trials for its biosimilars [3] - The company entered a critical phase from 2019 to 2021, negotiating licensing agreements with international giants to share risks and accelerate market access [3] - In 2023, Baiyoutai achieved significant milestones with FDA approvals for its biosimilars, marking a recognition of Chinese biopharmaceutical quality in major global markets [3] Group 3: Market Expansion - Pumen Technology has positioned internationalization at the core of its strategy since its listing in 2019, achieving international business revenue of 371 million yuan in 2024, a 14.87% increase [4] - The company focuses on major markets like the EU, Russia, and India, establishing a robust business network across over 120 countries [4][5] - Pumen Technology emphasizes localized operations by forming local teams and subsidiaries to better understand and meet regional market demands [5] Group 4: Innovation and R&D - Continuous innovation and R&D investment are deemed essential for long-term competitiveness in the global medical device market [8] - Baiyoutai maintains a high level of R&D investment, with 778 million yuan allocated in 2024, representing 104.64% of its revenue, focusing on international clinical trials and production optimization [8][9] - Both companies recognize the importance of adhering to the highest regulatory standards to navigate the complexities of different markets [10] Group 5: Future Directions - Baiyoutai plans to optimize its production system and advance more pipelines for global multi-center clinical trials, aiming to enhance brand influence and revenue through international collaborations [11] - Pumen Technology intends to increase R&D resources directed towards overseas markets, ensuring that product development aligns with international needs and trends [10]